Clinical Research Directory
Browse clinical research sites, groups, and studies.
Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes
Sponsor: Jaeb Center for Health Research
Summary
Pregnant women aged 18-40 with gestational diabetes (GDM) will take part in this study. We want to see how two different insulin treatments affect their blood sugar after they eat. These women usually use a rapid-acting insulin analog (RAA) that's injected to control their blood sugar before and after meals. They will come to the clinic for two meal sessions. For the first meal, we will randomly decide if they will use the usual RAA insulin or a newer inhaled insulin called technosphere insulin (TI). They will use the other type of insulin for their second meal. After each meal, we will compare their blood sugar levels.
Official title: The Safety and Efficacy of Rapid Acting Inhaled Technosphere Insulin (Afrezza) Compared With Subcutaneous Insulin to Achieve Pregnancy-Specific Postprandial Targets Among Patients With Gestational Diabetes
Key Details
Gender
FEMALE
Age Range
18 Years - 40 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2025-05
Completion Date
2025-07
Last Updated
2025-05-15
Healthy Volunteers
No
Conditions
Interventions
Inhaled Technosphere Insulin
Patients will receive TI (Afrezza) to be compared to RAA following a breakfast meal
Locations (5)
Sansum Diabetes Research Institute
Santa Barbara, California, United States
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Oregon Health and Science University
Portland, Oregon, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States